Evofem Biosciences and Orion Biotechnology join the OB-002 alliance


Evofem Biosciences, Inc. and Orion Biotechnology Canada Ltd. have entered into a collaboration agreement to assess the compatibility and Stability from Orion’s novel CCR5 Antagonist , OB-002, in Phexxi from Evofem (lactic acid, citric acid and potassium bitartrate) Vaginal Gel with the aim of developing a multipurpose prevention technology (MPT) product candidate for indications including the prevention of HIV in women.

The collaboration will focus on determining the compatibility and stability of OB-002 in Phexxi with expected results in 3Q22. Assuming positive results, companies will seek government and philanthropic funding for Clinical tests of the MPT vaginal gel candidate.

“For too long, women have had to put together a bag of products to protect themselves against pregnancy, various STIs and HIV,” said Saundra Pelletier, President and CEO of Evofem Biosciences. “This partnership with Orion aims to develop a one-of-a-kind product with the potential to revolutionize the way women protect their sexual and reproductive health: no unwanted pregnancies, no STIs and no HIV, all in one. single applicator.

Ian McGowan, Orion Chief Medical Officer Biotechnology , added: “It is unacceptable that we still see high rates of new HIV infections among women every year and there is clearly a compelling need to expand the HIV prevention portfolio. Orion is very happy to work with Evofem to resolve this important issue. and develop an MPT product for women around the world. “

In testing to date of Orion’s new CCR5 antagonist, OB-002 has demonstrated best-in-class In vitro Powerful. OB-002 was 100% effective in blocking transmission of HIV infection in a non-human primate model. A phase 1 study involving 15 subjects of OB-002 vaginally administered gel demonstrated that OB-002 gel was safe and well tolerated with no evidence of systemic absorption.

Phexxi is a hormone-free, on-demand prescription contraceptive vaginal gel that was launched in the United States in September 2020. First-order data is expected from Evofem’s pivotal phase 3 trial for the prevention of chlamydia and gonorrhea in women in the second half of 2022.


Comments are closed.